Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419
Expand allThis document outlines details of PBS-subsidised patisiran and vutrisiran for patients with hereditary transthyretin amyloidosis (HTA).
For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.
Hereditary transthyretin amyloidosis (HTA) quick reference
Table 1:
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB367 form | Written Electronic S100: patisiran vutrisiran | No | OPA | Must be treated by or in consultation with a:
| Yes |
Continuing PB368 form | Written Electronic S100: Patisiran | No | OPA | Not specified | Yes |
Continuing PB368 form | Written Electronic S100: vutrisiran | No | OPA | Must be treated by or in consultation with a:
| Yes |